- Home
- EVI vs EXEL Comparison
EVI vs EXEL Comparison
Compare EVI & EXEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVI
- EXEL
- Stock Information
- Founded
- EVI 1959
- EXEL 1994
- Country
- EVI United States
- EXEL United States
- Employees
- EVI N/A
- EXEL N/A
- Industry
- EVI Other Consumer Services
- EXEL Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- EVI Consumer Discretionary
- EXEL Health Care
- Exchange
- EVI Nasdaq
- EXEL Nasdaq
- Market Cap
- EVI 198.5M
- EXEL 9.8B
- IPO Year
- EVI N/A
- EXEL 2000
- Fundamental
- Price
- EVI $16.30
- EXEL $36.17
- Analyst Decision
- EVI
- EXEL Buy
- Analyst Count
- EVI 0
- EXEL 18
- Target Price
- EVI N/A
- EXEL $37.59
- AVG Volume (30 Days)
- EVI 9.2K
- EXEL 2.2M
- Earning Date
- EVI 05-20-2025
- EXEL 05-13-2025
- Dividend Yield
- EVI 1.89%
- EXEL N/A
- EPS Growth
- EVI 0.45
- EXEL 170.77
- EPS
- EVI 0.49
- EXEL 1.76
- Revenue
- EVI $360,461,000.00
- EXEL $2,168,701,000.00
- Revenue This Year
- EVI N/A
- EXEL $5.78
- Revenue Next Year
- EVI N/A
- EXEL $10.94
- P/E Ratio
- EVI $33.48
- EXEL $20.64
- Revenue Growth
- EVI N/A
- EXEL 18.50
- 52 Week Low
- EVI $14.51
- EXEL $20.14
- 52 Week High
- EVI $22.48
- EXEL $40.26
- Technical
- Relative Strength Index (RSI)
- EVI 45.14
- EXEL 43.89
- Support Level
- EVI $15.76
- EXEL $34.90
- Resistance Level
- EVI $17.09
- EXEL $40.26
- Average True Range (ATR)
- EVI 0.87
- EXEL 1.21
- MACD
- EVI 0.03
- EXEL -0.19
- Stochastic Oscillator
- EVI 48.52
- EXEL 23.69
About EVI EVI Industries Inc.
EVI Industries Inc through its subsidiaries, is a distributor that sells, leases, and rents commercial, industrial, and vended laundry and dry cleaning equipment and steam and hot water boilers manufactured by others, supplies related replacement parts and accessories, designs and plans turn-key laundry, dry cleaning, and boiler systems, and provides installation and maintenance services to its customers, which include commercial, industrial, institutional, government, and retail customers. These activities are conducted in the United States, Canada, the Caribbean, and Latin America.
About EXEL Exelixis Inc.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.